EU must tackle clinical trials shortfalls as current lack of evidence is "appalling"
This article was originally published in Clinica
With devices becoming increasingly complex, Competent Authorities must ensure there are sufficiently well-trained experts at Notified Body level, particularly for assessing innovative devices and for clinical trials. But authorities are facing difficult resource issues and finding experts is a real challenge. Dr Susanne Ludgate of the UK MHRA told Amanda Maxwell where the problems lie, and what she believes to be the solutions
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
With just a few months remaining until the full application of the EU Medical Device Regulation, notified body designations are still only trickling through. Ireland is the latest EU member state to have a resident MDR notified body.
In this second article of a two-part series, Eithne Lee of ISO Life Sciences global consultancy identifies some of the problems that medtech premarket innovators and SMEs are facing, with the EU MDR application date now less than four months away.